CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
13 nov. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: ...
Organovo Highlights FXR314 Combination Therapy Potential and Plan
08 nov. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Organovo to Participate in the H.C. Wainwright Global Investment Conference
08 sept. 2023 12h46 HE
|
Organovo, Inc.
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high...
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
23 août 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with...
Organovo Announces FXR Program
21 mars 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated...
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
15 nov. 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using...
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h20 HE
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Announces Postponement of Annual Meeting of Stockholders
06 sept. 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Achieves 3D Tissue Model for Crohn’s Disease
17 mai 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel...
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
01 mars 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for...